Monotherapy: Approval Hurdles for AEDs

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Thursday, August 2, 2012
Follow Pharmacy_Times:
There are great challenges to gaining approval for new antiepileptic drugs to be used as monotherapy, but a recent article offers ideas for ways forward.

Patient response to antiepileptic drugs (AED) varies considerably. Around half of all patients who are treated with monotherapy respond to reasonable doses and remain seizure-free. About a fourth of patients have intermittent control problems. The remaining fourth do not respond to single or combined AEDs; even after a year of various drug trials, they continue to have seizures.
 
For many reasons, monotherapy is preferred whenever possible. It decreases drug exposure, reduces the likelihood of drug interaction, and improves medication adherence. New drugs are generally tried as add-on therapy to ensure that patients remain seizure-free, progressing to “withdrawal to monotherapy” with the new drug. Researchers measure efficacy by monitoring the portion of patients meeting predefined escape criteria for seizure worsening compared with aggregated pseudo-placebo control data from 8 previously conducted conversion-to-monotherapy trials. Perhaps because of these onerous requirements, no drug has been tested or licensed as monotherapy in the United States for newly diagnosed idiopathic generalized epilepsy in at least 10 years.
 
The authors of an article published in the June 2012 edition of Epileptic Disorders describe the search for novel trial designs that would ensure safety for participants and decrease the time required to bring new monotherapy agents to market. Since placebo-controlled studies and those using suboptimal doses of comparator drugs are unacceptable, the authors suggest as possible alternatives sequential designs with interim analysis, comparison with pre-treatment seizure numbers, and enrollment of patients who are diagnosed with EEG-confirmed idiopathic generalized epilepsy at their first seizure in head-to-head trials with proven AEDs.

Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Previous Pharmacy Times coverage of AEDs:


Related Articles
Reduced sleep duration is linked to more repetitive negative thinking.
Researchers at the American Epilepsy Society meeting reported important strides in the understanding of epilepsy, including identification of new therapeutic targets in the brain, as discussed by Esther Krook-Magnuson, PhD, as well as improved understanding of the factors involved in sudden death of patients with epilepsy, and a greater recognition of the benefits of neurosurgery in patients with epilepsy.
Several new antiepileptic drugs have recently been approved in the United States. In a symposium at the American Epilepsy Society in Seattle, Washington, Professor Martin J. Brodie, MD, director of the epilepsy unit of the Western Infirmary in Glasgow, Scotland, discussed some considerations with ezogabine and eslicarbazepine.
Mark Cook, MD, of the University of Melbourne, and Brian Litt, MD, of the Penn Epilepsy Center and the Center for Neuroengineering and Therapeutics at the University of Pennsylvania, discuss how new devices, big data, and massive online competitions are enabling prediction of seizures before they start.
Latest Issues
$auto_registration$